BRAF, MEK Inhibition Shows Strong Long-Term Survival Benefit in Melanoma
In this video we discuss 3-year results of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma.
Pembrolizumab Yields Strong Long-Term Survival in Advanced Melanoma
In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.
By clicking Accept, you agree to become a member of the UBM Medica Community.